描述
non-ionic
质量水平
表单
semisolid (may be liquid)
分子量
average Mn ~362
环保替代产品特性
Use of Renewable Feedstocks
Design for Degradation
Learn more about the Principles of Green Chemistry.
sustainability
Greener Alternative Product
杂质
≤1.0% water
折射率
n20/D 1.451 (lit.)
mp
48 °C
酸值
≤2.0 mg KOH/g
羟基值
144‑165 mg KOH/g
溶解性
water: insoluble
密度
0.95 g/mL at 25 °C (lit.)
HLB
9.7
环保替代产品分类
SMILES字符串
CCCCCCCCCCCCOCCOCCOCCOCCO
InChI
1S/C20H42O5/c1-2-3-4-5-6-7-8-9-10-11-13-22-15-17-24-19-20-25-18-16-23-14-12-21/h21H,2-20H2,1H3
InChI key
WPMWEFXCIYCJSA-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
ECO Brij® L4, also known as polyethylene glycol lauryl ether, is a bio-based, nonionic surfactant manufactured from naturally occurring straight-chain lauryl alcohol. This detergent, derived from natural sources, provides various functional advantages, such as detergency, emulsification, and wetting, making it suitable for a range of applications in biochemical and biological research.
The ECO Brij series of ethoxylated fatty alcohols are non-ionic surfactants manufactured using renewable sources. ECO Brij L4 is a mixture of tetraethylene glycol alkyl ethers, primarily dodecyl (C12) ether. The alkyl ether profile of ECO Brij L4 may differ lot-to-lot due to natural variability in the lipid starting material (palm oil).
We are committed to bringing you Greener Alternative Products, which adhere to one or more of The 12 Principles of Green Chemistry. This product is a biobased surfactant and is aligned with the 7th principle of Green Chemistry "Use of Renewable Feedstocks" and the 10th principle "Design for Degradation".
特点和优势
- 100 % Renewable
- 100 % Bio-based
- Certified to the USDA BioPreferred Program
- Lower carbon footprint than petrochemical-based versions
- High-purity chemical suitable for a wide variety of research applications
其他说明
For additional information on our range of Biochemicals, please complete this form.
法律信息
Brij is a registered trademark of Croda International PLC
ECO BRIJ is a registered trademark of Croda Inc.
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2
储存分类代码
10 - Combustible liquids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
D Sato et al.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 44(1), 73-76 (2012-05-02)
Sclerotherapy is useful for the treatment of arteriovenous vascular malformations. However, intravascular administration of sclerotic agents into small arteriovenous niduses is often difficult. Extravascular administration of sclerotic agents causes reduction of vascular flow on Doppler echo during clinical sclerotherapy. Therefore
Darío Morais et al.
Rhinology, 50(1), 80-86 (2012-04-04)
Hereditary Haemorrhagic Telangiectasia or Rendu-Osler-Weber syndrome is a rare autosomal dominant vascular disease characterized by mucocutaneous and gastrointestinal telangiectases and localized arteriovenous malformations in lung, brain and liver. Epistaxis, due to rupture of telangiectases of the nasal mucosa, is the
Takashi Yamaki et al.
Journal of vascular surgery, 56(6), 1649-1655 (2012-05-23)
This study assessed changes in the calf muscle deoxygenated hemoglobin (HHb) level during light-intensity exercise after ultrasound-guided foam sclerotherapy (UGFS) for superficial venous insufficiency. UGFS with 1% or 3% polidocanol foam (POL-F) was used to treat unilateral great saphenous vein
Masahide Fujiki et al.
Journal of plastic surgery and hand surgery, 46(3-4), 145-151 (2012-06-13)
The minimally-invasive nature of sclerotherapy makes it one of the first treatment options for venous malformations, although treatment-related complications, such as peripheral nerve paralysis, have been reported in some clinical cases. However, no studies of the aetiology of the detrimental
N Shadid et al.
The British journal of surgery, 99(8), 1062-1070 (2012-05-26)
New minimally invasive treatment modalities, such as ultrasound-guided foam sclerotherapy (UGFS), are becoming more popular. In a multicentre randomized controlled non-inferiority trial, the effectiveness and costs of UGFS and surgery for treatment of the incompetent great saphenous vein (GSV) were
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持